natgillin/translations-raw huggingface dataset:
• Fever, signs of infection (e.g. sore throat), pale skin or extreme tiredness. 
• povišana telesna temperatura, znaki okužbe (npr. vnetje grla), bledost kože ali huda utrujenost.
Warnings and precautions Tell your doctor before you start to take this medicine if: 
Opozorila in previdnostni ukrepi Pred uporabo tega zdravila se posvetujte z zdravnikom v naslednjih primerih:
This could indicate that you are suffering from a serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body) 
To lahko pomeni, da je pri vas prisotna trombotična trombocitopenična purpura (redka motnja strjevanja krvi, ki lahko povzroči pojav številnih krvnih strdkov po celem telesu).
Major bleeding was mostly of extracranial origin in both groups (5.3% in the clopidogrel + ASA group; 3.5% in the placebo +ASA group), mainly from the gastrointestinal tract (3.5% vs. 1.8%). 
Hujše krvavitve so bile v obeh skupinah večinoma ekstrakranialne (5,3 % v skupini s klopidogrelom + acetilsalicilno kislino, 3,5 % v skupini s placebom + acetilsalicilno kislino), predvsem v prebavilih (3,5 % v prim.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)). 
Delež bolnikov s primarnim opazovanim dogodkom [srčno-žilna (SŽ) smrt, miokardni infarkt (MI) ali kap] je bil 582 (9,3 %) v skupini, zdravljeni s klopidogrelom, in 719 (11,4 %) v skupini, ki je prejemala placebo, to je 20 % zmanjšanje relativnega tveganja (95 % IZ od 10 % - 28 %; p=0,00009) v skupini, zdravljeni s klopidogrelom (17 % zmanjšanje relativnega tveganja, če so bili bolniki zdravljeni konzervativno, 29 % kadar je bila izvedena perkutana transluminalna koronarna angioplastika (PTKA) z ali brez stenta in 10 %, če je bila izvedena premostitvena operacija koronarnih arterij (POKA)).
What you need to know before you take Clopidogrel Teva Pharma B.V. 
Kaj morate vedeti preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V.
If you suffer from hardening of the arteries (“atherosclerosis”) there is an increased risk of a blood clot forming in your blood vessels. 
Če imate aterosklerozo (otrdele krvne žile), je pri vas prisotno povečano tveganje za nastanek krvnega strdka v krvnih žilah večje.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) or placebo (N=6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies. 
Bolniki so bili naključno razporejeni v skupino, ki je prejemala klopidogrel (udarni odmerek 300 mg, nato 75 mg/dan, n=6.259) ali skupino, ki je prejemala placebo (n=6.303), oboje prejeto v kombinaciji z acetilsalicilnsko kislino (75-325 mg enkrat na dan) in drugimi standardnimi terapijami.
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Qwave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
- Akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca):zdravljenje moramo začeti z enkratnim udarnim odmerkom 300 mg klopidogrela in nadaljevati s 75 mg enkrat na dan (s 75 mg do 325 mg acetilsalicilne kisline (ASA) dnevno).
• Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound 
• odrgnine, hematomi (neobičajne krvavitve pod kožo), krvavitve iz nosu, krvavitve iz želodca ali črevesja, povečane krvavitve na mestu vboda,
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
Bolniki so dobivali klopidogrel (300 mg udarni odmerek, nato pa 75 mg na dan, n=1.752) ali placebo (n=1.739), oboje v kombinaciji z acetilsalicilno kislino (150 do 325 mg kot udarni odmerek, nato 75 do 162 mg na dan) in fibrinolitičnim sredstvom in po potrebi s heparinom.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), izpuščaj, eritematozni izpuščaj, urtikarija, ekcem, lichen planus
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries. 
Primarni opazovani dogodek je bil opažen pri 15,0 % bolnikov v skupini s klopidogrelom in 21,7 % bolnikov v skupini s placebom, kar predstavlja absolutno zmanjšanje za 6,7 % in 36 % zmanjšanje verjetnosti v prid klopidogrela (95 % IZ od 24 % do 47 %; p<0,001) v glavnem zaradi zmanjšanja pojavnosti zaradi infarkta zamašenih arterij.
- Keep this leaflet. 
Previdno odlepite zadnjo stran.
• Altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas). 
• spremembe vedenja, glavoboli, koma, motnje vida, napadi (krči), odpovedovanje ledvic, povišana telesna temperatura, huda utrujenost, šibkost ali krvavitve iz želodca, črevesja ali kože (vključno z manjšimi rdečimi madeži ali večjimi odrgninami).
Please note that instructions on how to remove the tablet from the blister strip are given on the outer carton of the peelable blisters. 
• Navodila za odstranjevanje tablet iz pretisnega omota se nahajajo na škatlici, v katerem so shranjeni pretisni omoti, ki se odlepijo.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
Pri analizi po načelu začetnega namena zdravljenja so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala acetilsalicilno kislino, 1.020 dogodkov (zmanjšanje relativnega tveganja (zmanjšanje RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, pri dodatnih 10 [IZ: 0 do 20] bolnikih.
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA) - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
• odraslih bolnikih z akutnim koronarnim sindromom: akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA - acetylsalicylic acid).
Lactose monohydrate Hypromellose (E464) Titanium dioxide (E171) Macrogol 4000 
Filmska obloga laktoza monohidrat hipromeloza (E464) titanov dioksid (E171) makrogol 4000 rdeči železov oksid (E172) rumeni železov oksid (E172)
Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide). 
Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida).
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8). 
Pri bolnikih je treba preveriti anamnezo preobčutljivosti na druge tienopiridine (kot sta npr. tiklopidin in prasugrel), ker so poročali o navzkrižnih alergijah med tienopiridini (glejte poglavje 4.8).
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge. 
Bolniki so 28 dni oziroma do odpusta dobivali klopidogrel (75 mg na dan, n=22.961) ali placebo (n=22.891) v kombinaciji z acetilsalicilnsko kislino (162 mg na dan).
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups. 
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + acetilsalicilna kislina, 0,7 % placebo + acetilsalicilna kislina) in hemoragičnih možganskih kapi (0,8 % v prim.
• Ticlopidine, other antiplatelet agent. 
• tiklopidin, druga antiagregacijska zdravila.
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose. 
Pri ljudeh, ki so prejemali terapevtski odmerek klopidogrela, niso opazili nobenega učinka na jetrne presnovne encime.
Your doctor should have prescribed Clopidogrel Teva Pharma B.V. plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
If you become pregnant while taking Clopidogrel Teva Pharma B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon. 
Pri podganah in pavijanih so poročali tudi o slabem želodčnem prenašanju (gastritis, želodčne erozije in/ali bruhanje), pri uporabi zelo velikih odmerkov.
Aluminium-aluminium peelable perforated unit-dose blisters, aluminium-aluminium perforated unit dose blisters and HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant. 
Perforirani pretisni omoti iz aluminija za enkratno odmerjanje, ki se odlepijo in perforirani pretisni omoti za enkratno odmerjanje iz aluminija ter HDPE stekleničke z zaporkami iz polipropilena ter silikagel sušilno sredstvo.
In adults Clopidogrel Teva Pharma B.V. reduces the risk of blood clots forming which in turn reduces the risk of serious conditions such as heart attack and stroke from occurring. 
jemljejo odrasali za preprečavanje nastanka krvnih strdkov (trombov) ter tako preprečuje pojav resnih dogodkov, kot je srčni napad in kap.
Push the tablet out 
Potisnite tableto iz omota.
However, clopidogrel and ASA have been administered together for up to one year (see section 
Vseeno so klopidogrel in acetilsalicilno kislino sočasno uporabljali do enega leta (glejte poglavje 5.1).
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis. 
Uporaba 75 mg klopidogrela na dan ni spremenila farmakokinetike S-varfarina ali internacionalnega normaliziranega razmerja (INR) pri bolnikih, ki so dolgotrajno prejemali varfarin.
Clopidogrel Teva Pharma B.V. is supplied in peelable perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet; perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet or HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant containing 30 or 100 tablets. 
je na voljo v perforiranih pretisnih omotih iz aluminija, ki se odlepijo, in sicer po 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 tablet; ter perforiranih pretisnih omotih iz aluminija, in sicer po 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 tablet ali v HDPE stekleničkah z zaporkami iz polipropilena, varnimi pred otroci ter silikagel sušilnim sredstvom, ki vsebujejo 30 ali 100 tablet.
The number of patients who reached the primary endpoint (time to first occurrence of stroke, MI, non-CNS systemic embolism or vascular death) was 832 (22.1%) in the group treated with clopidogrel + ASA and 924 (24.4%) in the placebo + ASA group (relative risk reduction of 11.1%; 95% CI of 2.4% to 19.1%; p=0.013), primarily due to a large reduction in the incidence of strokes. 
Primarni opazovani dogodek (čas do prvega pojava možganske kapi, MI, sistemske embolije (ne v osrednjem živčevju) ali žilne smrti) je doseglo v skupini s klopidogrelom + acetilsalicilno kislino 832 (22,1 %) bolnikov in v skupini s placebom + acetilsalicilno kislino 924 (24,4 %) bolnikov (relativno zmanjšanje tveganja 11,1 %, 95 % IZ: od 2,4 % do 19,1 %, p = 0,013), predvsem kot posledica velikega zmanjšanja incidence možganskih kapi.
Hepatic impairment 
Ušesne bolezni vrtoglavica
What Clopidogrel Teva Pharma B.V. is and what it is used for What you need to know before you take Clopidogrel Teva Pharma B.V. How to take Clopidogrel Teva Pharma B.V. 
in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Teva Pharma B.V.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Pharma B.V. 
Iz previdnostnih razlogov naj se z dojenjem med zdravljenjem z zdravilom Klopidogrel Teva Pharma B.V.
Other medicines and Clopidogrel Teva Pharma B.V. 
Druga zdravila in zdravilo Kopidogrel Teva Pharma B.V.
Clopidogrel should therefore be used with caution in this population (see section 4.2). 
Zato je potrebno pri tej skupini bolnikov klopidogrel uporabljati previdno (glejte poglavje 4.2).
If you get any side effects, talk to your doctor or pharmacist. 
Če opazite kateri koli neželeni učinek, se posvetujete z zdravnikom ali farmacevtom.
Prolonged bleeding, bleeding inside the head, bleeding in the eye, blood in the urine and/or purpura (red spots on the skin caused by bleeding underneath the skin) Rashes, itching, abnormal touch sensation 
• podaljšan čas krvavitve, krvavitve v dihalih, krvavitve v očesu, kri v urinu in/ali purpura (rdeče pike na koži, ki nastajajo zaradi krvavitev pod kožo),
Driving and using machines Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery. 
Vpliv na sposobnost upravljanja vozil in strojev Malo verjetno je, da bi zdravilo Klopidogrel Teva Pharma B.V.
Do not take Clopidogrel Teva Pharma B.V. 
Ne jemljite zdravila Klopidogrel Teva Pharma B.V.
If you forget to take Clopidogrel Teva Pharma B.V. 
Če ste pozabili vzeti zdravilo Klopidogrel Teva Pharma B.V.
You should continue taking Clopidogrel Teva Pharma B.V. for as long as your doctor has told you to take it. 
morate jemati vse dokler vam ga vaš zdravnik predpisuje.
30 tablets HDPE bottle: 
HDPE steklenička po 30 tablet:
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co administered with atenolol, nifedipine, or both atenolol and nifedipine. 
Pri sočasni uporabi klopidogrela z atenololom, nifedipinom, ali z obema - atenololom in nifedipinom - niso opazili nobenih klinično pomembnih farmakodinamičnih interakcij.
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel 
75 mg filmsko obložene tablete klopidogrel
30 tablets HDPE bottles: 
HDPE stekleničke po 30 tablet:
The other ingredients in the tablet core are (see section 2 ‘Clopidogrel Teva Pharma B.V. contains lactose' and ‘Clopidogrel Teva Pharma B.V. contains hydrogenated castor oil') lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose (E463), crospovidone (type A), hydrogenated castor oil and sodium laurilsulfate, and in the film-coating are lactose monohydrate, hypromellose (E464), titanium dioxide (E171), macrogol 4000, iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminium lake (E132). 
Pomožne snovi v filmski oblogi so: laktoza monohidrat, hipromeloza (E464), titanov dioksid (E171), makrogol 4000, rdeči železov oksid (E172), rumeni železov oksid (E172), indigotin (E132).
If you forget to take a dose of Clopidogrel Teva Pharma B.V., but don't remember within 12 hours of the missed dose, skip the missed dose and take the next tablet at the usual time. 
in se nanj spomnite po več kot 12 urah, izpustite pozabljeni odmerek in naslednji odmerek vzemite ob običajnem času.
100 tablets HDPE bottles: 
HDPE stekleničke po 100 tablet:
If you forget to take a dose of Clopidogrel Teva Pharma B.V., but remember within 12 hours of the missed dose, take your tablet straight away and then take your next tablet at the usual time. 
in se nanj spomnite do 12 ur od vašega običajnega časa jemanja, takoj vzemite tableto.
The recommended dose for ASA was 75 to 100 mg/day. 
Priporočeni odmerek acetilsalicilne kisline je bil od 75 do 100 mg na dan. Bolnike so zdravili do 5 let.
How to take Clopidogrel Teva Pharma B.V. 
Kako jemati zdravilo Klopidogrel Teva Pharma B.V.
Inflammation of the blood vessels, decrease in blood pressure Yellowing of the skin and whites of the eyes (jaundice) Bleeding in the lungs, throat, stomach or bowels, abdomen or joints Bleeding of post-operative wounds or other serious bleeds Severe abdominal pain with or without back pain, pain in the joints and muscular pain Diarrhoea 
Bolezni prebavil krvavitev v prebavila, driska, bolečine v trebuhu, dispepsija želodčna razjeda in razjeda na dvanajstniku, gastritis, bruhanje, navzea, zaprtje, flatulenca retroperitonealna krvavitev krvavitev v prebavila in retroperitonealna krvavitev s smrtnim izidom, pankreatitis, kolitis (vključno z ulceroznim ali limfocitnim
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group. 
V študiji CLARITY je v skupini s klopidogrelom v kombinaciji z acetilsalicilno kislino prišlo do splošnega povečanja krvavitev v primerjavi s skupino s placebom v kombinaciji z acetilsalicilno kislino.
- Perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet. 
- Perforirani pretisni omoti vsebujejo 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložena tableta.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING BOTTLE LABEL (30 or 100 film-coated tablets) 
ETIKETA STEKLENIČKE (30 in 100 filmsko obloženih tablet)
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised. 
Pri tistih bolnikih, ki so že kazali znake preobčutljivosti na druge tienopiridine, je treba spremljati znake preobčutljivosti na klopidogrel skozi celotno terapijo.
• moclobemide, medicine to treat depression. 
• fluoksetin, fluvoksamin ali moklobemid, zdravila za zdravljenje depresije,
Reduced levels of certain white blood cells which increases the risk of infection (neutropenia) Vertigo (dizziness accompanied by a whirling sensation) Bleeding inside the abdomen 
• zmanjšanje števila belih krvnih celic, zaradi česar je tveganje za okužbo večje (nevtropenija),
- Peelable perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet. 
- Perforirani pretisni omoti, ki se odlepijo, vsebujejo 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložena tableta.
- If you have any side effects, including any side effects not listed in this leaflet, talk your doctor or pharmacist. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 75 mg clopidogrel (as hydrobromide) 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 75 mg klopidogrela (v obliki bromida).
See section 4 
Glejte poglavje
+ ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively). 
V skupini s klopidogrelom + acetilsalicilno kislino je bilo več intrakranialnih krvavitev (1,4 %) kot v skupini s placebom + acetilsalicilno kislino (0,8 %).
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél/Tel: +49 731 402 02 
Luxembourg/Luxemburg Teva Pharma Belgium S.A. Tél/Tel: +32 3 820 73 73
Cross reactions among thienopyridines 
• Okvarjeno delovanje jeter
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel oral use 
IME ZDRAVILA IN POT(I) UPORABE Klopidogrel Teva Pharma B.V.
Symptoms may include altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness, or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas) 
Simptomi lahko vključujejo spremembe vedenja, glavobole, komo, motnje vida, napade (krče), odpovedovanje ledvic,
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of peelable blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet) 
ZUNANJA OVOJNINA - pretisni omoti, ki se odlepijo (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložena tableta)
Clopidogrel Teva Pharma B.V. with food and drink You can take Clopidogrel Teva Pharma B.V. with or without food. 
s hrano in pijačo Zdravilo Klopidogrel Teva Pharma B.V.
INFORMATION IN BRAILLE Clopidogrel Teva Pharma B.V. 75 mg 
PODATKI V BRAILLOVI PISAVI Klopidogrel Teva Pharma B.V.
How to store Clopidogrel Teva Pharma B.V. 
Shranjavenja zdravila Klopidogrel Teva Pharma B.V.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet) 
ZUNANJA ŠKATLICA za pretisne omote (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ali 100x1 filmsko obložena tableta)
Ulcers in the stomach and small intestine, nausea, vomiting, constipation, flatulence (wind) and inflammation of the stomach leading to sickness, loss of appetite and discomfort after eating Reduction in blood platelets which makes bleeding or bruising more likely Blood disorders including a reduction in the number of white blood cells which makes infections more likely. 
• razjede v želodcu in tankem črevesju, navzea, bruhanje, zaprtje, preveč plinov (vetrovi) in vnetje želodca, kar vodi do občutka slabosti, izgube apetita in nelagodja po hranjenju,
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 30 film-coated tablets 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
Clopidogrel Teva Pharma B.V. contains lactose. 
Klopidogrel Teva Pharma B.V.
NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel 
75 mg filmsko obložene tablete klopidogrel peroralna uporaba
Taste disorders 
• motnje okušanja,
Further information on RoActemra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/RoActemra. 
Nadaljnje informacije o zdravilu RoActemra so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/RoActemra.
The pack will also include a patient alert card with key safety information for patients. 
V izobraževalnem gradivu bo tudi opozorilna kartica s ključnimi varnostnimi informacijami za bolnika.